Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

Trial StartNu-3Positive

AI Analysis

Summary

Lakewood-Amedex Biotherapeutics announced IRB approval and clinical site readiness to initiate a Phase 2a clinical trial of Nu-3 for treating infected diabetic foot ulcers. Nu-3 is part of the company's Bisphosphocin® class of broad-spectrum antimicrobials.

Clinical Trial Data

Phase

Phase 2a

Outcome Details

IRB approval and clinical site readiness announced for Phase 2a initiation

Importance:5/10

Sentiment:

0.60

clinical trialphase 2aantimicrobialsinfectious diseaseIRB approval

Related Companies

$LABT

Read the original article

Published by PR Newswire Biotech on September 18, 2026 12:13 PM

Read Original